| Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway | |
| Shao, Jingwei; Zheng, Guirong; Chen, Hongning; Liu, Jian; Xu, Aixiao; Chen, Fan; Li, Tao; Lu, Yusheng; Xu, Jianguo; Zheng, Ning | |
| 刊名 | ONCOTARGET
 |
| 2017 | |
| 卷号 | 8页码:78351-78364 |
| 关键词 | cell proliferation me tapristone cell apoptosis non-small cell lung cancer EGFR |
| ISSN号 | 1949-2553 |
| URL标识 | 查看原文 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/2893859 |
| 专题 | 福州大学 |
| 推荐引用方式 GB/T 7714 | Shao, Jingwei,Zheng, Guirong,Chen, Hongning,et al. Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway[J]. ONCOTARGET,2017,8:78351-78364. |
| APA | Shao, Jingwei.,Zheng, Guirong.,Chen, Hongning.,Liu, Jian.,Xu, Aixiao.,...&Jia, Lee.(2017).Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway.ONCOTARGET,8,78351-78364. |
| MLA | Shao, Jingwei,et al."Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway".ONCOTARGET 8(2017):78351-78364. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论